MedTrace Logo

Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS

NCT02419638 · Status: WITHDRAWN · Type: OBSERVATIONAL

Last updated 2016-02-29

No results posted yet for this study

Summary

To compare two commonly used MS medications, IFN β-1a subcutaneous three times per week (Rebif) and oral twice daily dimethyl fumarate (Tecfidera), on mean number of new or enlarging T2 lesions at 6 months in adults with relapsing-remitting multiple sclerosis who are prescribed these medications and receive a 6 month MRI scan as standard of care.

Conditions

Interventions

DRUG

Rebif (IFN β-1a subcutaneous three times per week)

DRUG

Tecifdera (dimethyl fumarate)

Sponsors & Collaborators

  • EMD Serono

    collaborator INDUSTRY

  • Brigham and Women's Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2015-12-31
Completion
2016-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02419638 on ClinicalTrials.gov